Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings

Contributed by: Business Wire

Logo

Tags

Cardiology

Biotechnology

FDA

Health

Pharmaceutical

Neurology

Health Technology

Medical Devices

Research

Science

Clinical Trials

TIGERTRIEVER™️13

More Like This

Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke

Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions

Rapid Medical™ Reports No Safety Concerns for Medium Vessel Occlusions in the Interim Safety Analysis of the DISTALS Study with TIGERTRIEVER™13

Rapid Medical™ Announces Japanese Approval and Exclusive Partnership With Kaneka for TIGERTRIEVER–The World’s Only Adjustable Thrombectomy Device

Rapid Medical's TIGERTRIEVER™ Delivers First-Pass Success in Challenging Ischemic Stroke Patients with ICAD

The AI-powered TIGERTRIEVER removes stroke-causing blood clots during first-in-man procedures in Colombia. Rapid Medical’s portfolio of active technology allows greater procedural personalization, which is enhanced with AI workflow. (Photo: Business Wire)

Rapid Medical™ Completes Successful Ischemic Stroke Procedures with the World’s First Robotic Thrombectomy Device

Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval

DRIVEWIRE 24 redefines interventional access by providing an active deflectable tip that controls and steers a range of catheters directly to the target vessels. Whereas conventional access devices are reactive and rely on external forces to reach their target, DRIVEWIRE's active technology selects turns on-demand and handles the complexity of navigating the vascular highway with ease. (Graphic: Business Wire)

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution